Semaglutide — Interactions & Safety Profile
Medical Disclaimer
Contraindications
Personal or family history of medullary thyroid carcinoma (MTC)
GLP-1 agonists caused thyroid C-cell tumours in rodents. Contraindicated if personal or family history of MTC.
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
MEN 2 predisposes to medullary thyroid carcinoma.
History of pancreatitis
GLP-1 agonists associated with acute pancreatitis in post-marketing reports. Use with extreme caution.
Drug Interactions
Increased risk of hypoglycaemia when combined.
Mechanism: Additive glucose-lowering effect.
Reduce insulin or sulfonylurea dose when initiating semaglutide.
Slowed gastric emptying may delay absorption of co-administered oral medications.
Mechanism: Delayed gastric emptying.
Monitor oral drug levels (e.g. warfarin, levothyroxine, oral contraceptives). Clinically significant interactions rare but possible.
Monitoring Required
- •HbA1c (if diabetic) every 3-6 months
- •Renal function (eGFR) periodically
- •Signs of pancreatitis (persistent severe abdominal pain)
- •Thyroid examination if symptoms develop
Pregnancy & Nursing
Contraindicated. Teratogenic in animal studies. Discontinue ≥2 months before planned pregnancy.
Pending physician review — consult your provider before use.